David Hallal
CIK 1457477 · Chief Executive Officer · last filed 2026-06-04
David Hallal is a Chief Executive Officer who has filed 115 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for KLRS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$16.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $91.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$91.31M
5
115
-$16.84M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Director | — | $3.32 | — | $0 | 2 | 2026-06-04 |
| SRRK | Chief Executive Officer | 1,844,034 | $49.10 | $90.54M | -$3.97M | 15 | 2026-04-20 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | 0 | $10.15 | $0 | -$3.94M | 9 | 2025-08-29 |
| SEER | Director | 355,128 | $2.15 | $763.5K | $0 | 5 | 2024-06-14 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 99,210 | $9.81 | $973.3K | -$8.93M | 15 | 2024-06-07 |
Recent Filings
115 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-04 | KLRS | Grant (A) | — | $0 | EDGAR |
| 2026-04-20 | SRRK | Sell (S) | −30,615 | -$1.52M | EDGAR |
| 2026-02-11 | SRRK | Grant (A) | +128,004 | $0 | EDGAR |
| 2026-01-15 | SRRK | Sell (S) | −57,450 | -$2.45M | EDGAR |
| 2025-10-09 | SRRK | Gift (G) | −205,000 | $0 | EDGAR |
| 2025-08-29 | iTeos Therapeutics, Inc. (ITOS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-06 | iTeos Therapeutics, Inc. (ITOS) Delisted | Notice (144) | −38,228 | -$391.5K | EDGAR |
| 2025-06-06 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$671.3K | EDGAR |
| 2025-06-05 | iTeos Therapeutics, Inc. (ITOS) Delisted | Notice (144) | −38,227 | -$388.1K | EDGAR |
| 2025-06-04 | iTeos Therapeutics, Inc. (ITOS) Delisted | Notice (144) | −38,227 | -$384.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.